These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21740450)

  • 1. CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).
    Raffa RB; Ward SJ
    J Clin Pharm Ther; 2012 Jun; 37(3):260-5. PubMed ID: 21740450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.
    Zádor F; Otvös F; Benyhe S; Zimmer A; Páldy E
    Neurochem Int; 2012 Aug; 61(3):378-88. PubMed ID: 22613132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
    Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
    Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.
    Baur R; Gertsch J; Sigel E
    Br J Pharmacol; 2012 Apr; 165(8):2479-84. PubMed ID: 21470203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.
    Moreira FA; Grieb M; Lutz B
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):133-44. PubMed ID: 19285266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice.
    Wiley JL; Marusich JA; Zhang Y; Fulp A; Maitra R; Thomas BF; Mahadevan A
    Eur J Pharmacol; 2012 Nov; 695(1-3):62-70. PubMed ID: 22975289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
    Rock EM; Sticht MA; Duncan M; Stott C; Parker LA
    Br J Pharmacol; 2013 Oct; 170(3):671-8. PubMed ID: 23902479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rimonabant (Acomplia)].
    Duh D; Vanddevijver A
    J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
    [No Abstract]   [Full Text] [Related]  

  • 10. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
    Wright KL; Robertson DA; Moyer MP; Ward SG
    Int J Cancer; 2008 Apr; 122(8):1920-1. PubMed ID: 18076045
    [No Abstract]   [Full Text] [Related]  

  • 11. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid CB₁ receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations.
    Häring M; Grieb M; Monory K; Lutz B; Moreira FA
    Neuropharmacology; 2013 Feb; 65():83-9. PubMed ID: 23000076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
    Roser P; Vollenweider FX; Kawohl W
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 15. Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists.
    Lazary J; Juhasz G; Hunyady L; Bagdy G
    Trends Pharmacol Sci; 2011 May; 32(5):270-80. PubMed ID: 21497918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
    Scotter EL; Goodfellow CE; Graham ES; Dragunow M; Glass M
    Br J Pharmacol; 2010 Jun; 160(3):747-61. PubMed ID: 20590577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid CB(1) receptor activation stimulates neurite outgrowth and inhibits capsaicin-induced Ca(2+) influx in an in vitro model of diabetic neuropathy.
    Zhang F; Challapalli SC; Smith PJ
    Neuropharmacology; 2009 Aug; 57(2):88-96. PubMed ID: 19501110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
    Cox ML; Haller VL; Welch SP
    Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
    Walsh S; Gorman AM; Finn DP; Dowd E
    Brain Res; 2010 Dec; 1363():40-8. PubMed ID: 20888328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.